Skip to content

Reported November 11, 2025 · Before market open

Next report

Aug 6, 2026 (In 3 weeks)

Financials

Q3 2025

Income statement

See full
Revenue$14.6M-13.5%
Gross profit$3.4M-44.8%
Operating income-$781.0K-124%
Net income-$1.1M-137%
EPS (diluted)-$0.02-150%

Balance sheet

See full
Cash & equivalents$429.0K-85.3%
Total debt$10.4M-0.7%
Total equity$17.2M+13.6%
Total assets$54.0M+12.4%

Cash flow

See full
Operating cash flow-$2.5M-160%
CapEx$418.0K-70.2%
Free cash flow-$2.9M

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$226.95M
Enterprise value$236.89M
P/S3.7×

Profitability

See full
Gross margin24.8%-4.3pp
Operating margin2.2%-5.0pp
FCF margin-20.1%

Returns & leverage

See full
Debt / equity0.6×-0.1×
Current ratio1.8×+0.6×

Segments

By product

See full
Consumer Products$13.9M
Personal Care Ingredients$384.0K
Advanced Materials$270.0K

By geography

See full
Non Us$1.7M+125%

Versus estimates

Ask the moment Solesence, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Solesence, Inc. Common Stock report Q3 2025 earnings?
Solesence, Inc. Common Stock (SLSN) reported Q3 2025 earnings on November 11, 2025 before market open.
What were Solesence, Inc. Common Stock's Q3 2025 revenue and EPS?
Solesence, Inc. Common Stock reported revenue of $14.6M and diluted EPS of $-0.02 for Q3 2025.
How did Solesence, Inc. Common Stock's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 13.5% from $16.9M a year earlier.
Where can I find Solesence, Inc. Common Stock's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001171843-25-007246) and the 10-Q periodic report (0001999371-25-017415) directly on SEC EDGAR. The filing index links above go to sec.gov.